Onno Stolpe - Galapagos CEO

GLPG -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Mr. Onno van de Stolpe has served as Chief Executive Officer, Executive Director, Member of the Executive Committee of Galapagos NV since June 1999. He founded Galapagos in 1999 while he was Managing Director Genomics at Introgene . Prior to joining Introgene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the United States. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Mr. van de Stolpe started his career as Manager Business Development at MOGEN in Leiden. He currently also serves as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and has previously served as a member of the board of directors of DCPrime B.V
Age: 57  CEO Since 1999      
32 1 534 29 00  http://www.glpg.com
Onno van de Stolpe received a MS degree from the Agricultural University in Wageningen.

Management Efficiency

The company has return on total asset (ROA) of 6.84 % which means that it generated profit of $6.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 15.06 % meaning that it created $15.06 on every $100 dollars invested by stockholders.
The company currently holds 225.92 K in liabilities with Debt to Equity (D/E) ratio of 0.9 which is about average as compared to similar companies. Galapagos NV has Current Ratio of 8.77 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 9 records

CEO Since

Douglas FambroughDicerna Pharmaceuticals
Alex SapirDova Pharmaceuticals
Eddie GrayDynavax Technologies Corporatio
Rick PaulsDiaMedica Therapeutics
Barry SimonNantKwest
Jeffrey BachaDelMar Pharmaceuticals
Geoffrey RotsteinEquillium
Ryan WattsDenali Therapeutics
David ZaccardelliDova Pharmaceuticals

Entity Summary

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 918 people.Galapagos NV (GLPG) is traded on BATS Exchange in USA. It is located in Generaal De Wittelaan L11 A3 and employs 918 people. Galapagos is listed under Pharmaceutical Products category by Fama And French industry classification.

Galapagos NV Leadership Team

Rajesh Parekh, Non-Executive Chairman of the Board
Andre Hoekema, Sr. VP of Corporate Devel.
Katrine Bosley, Independent Non-Executive Director
Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer
Howard Rowe, Non-Executive Independent Director
Harrold Barlingen, Non-Executive Director
Elizabeth Goodwin, VP Corporate Communications & Investor Relations
Mary Kerr, Non-Executive Independent Director
Piet Wigerinck, Chief Scientific Officer
Christine Mummery, Non-Executive Independent Director
Bart Filius, CFO
Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director
Werner Cautreels, Non-Executive Independent Director

Stock Performance Indicators

Current Sentiment - GLPG

Galapagos NV Investor Sentiment

Most of Macroaxis users are currently bullish on Galapagos NV. What is your judgment towards investing in Galapagos NV? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
Search macroaxis.com